Clinical Trials Logo

Filter by:
NCT ID: NCT03535740 Active, not recruiting - Clinical trials for ALK-positive Advanced NSCLC

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

ALTA-2
Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.

NCT ID: NCT03535714 Active, not recruiting - Anorexia Nervosa Clinical Trials

Maudsley Model of Anorexia Nervosa Treatment for Adolescents and Young Adults (MANTR-a)

Start date: April 25, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to test effectiveness of a new treatment program for adolescents and young adults within the age of 14-21 suffering from AN (MANTR-a) compared to treatment as usual (TAU).

NCT ID: NCT03529045 Active, not recruiting - Epilepsy Clinical Trials

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

CORE-VNS
Start date: February 5, 2018
Phase:
Study type: Observational [Patient Registry]

Multicenter global post-market registry of subjects diagnosed with drug resistant epilepsy and treated with the VNS Therapy System.

NCT ID: NCT03528694 Active, not recruiting - Clinical trials for Non-muscle-invasive Bladder Cancer

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

POTOMAC
Start date: May 14, 2018
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer

NCT ID: NCT03524092 Active, not recruiting - Ulcerative Colitis Clinical Trials

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

LUCENT 2
Start date: October 19, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

NCT ID: NCT03518086 Active, not recruiting - Ulcerative Colitis Clinical Trials

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Start date: June 18, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

NCT ID: NCT03515993 Active, not recruiting - Gynecologic Cancer Clinical Trials

Follow-up in Gynecological Cancer Survivors

Start date: February 21, 2019
Phase:
Study type: Observational

A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary treatment

NCT ID: NCT03507413 Active, not recruiting - Clinical trials for Abdominal Aortic Aneurysm

Metformin Therapy in Non-diabetic AAA Patients

MetAAA
Start date: September 26, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

A prospective randomized, double blind, placebo-controlled, safety and efficacy study of metformin as add-on therapy in abdominal aortic aneurysm (AAA) OBJECTIVES Primary Objective - To demonstrate treatment efficacy of metformin in AAA in comparison to placebo or active comparator, as measured by growth of the AAA maximum diameter at 12 months Secondary Objectives - To asses inflammatory cytokines and parameters of neutrophil activation in AAA in response to metformin treatment by glucose - insulin - Interleukin-6 - markers of neutrophil activation (MPO, elastase, NGAL)

NCT ID: NCT03505801 Active, not recruiting - Atrial Fibrillation Clinical Trials

Confirm Rx Insertable Cardiac Monitor SMART Registry

Start date: April 24, 2018
Phase:
Study type: Observational [Patient Registry]

The purpose of the Confirm Rx SMART Registry is to collect real world data to assess the safety and performance of the Confirm Rx Insertable Cardiac Monitor (ICM) and system over a 12 month period. A sub-set of subjects enrolled in the Confirm Rx SMART Registry will meet the Post Market Clinical Follow-Up (PMCF) requirement for CE mark.

NCT ID: NCT03498521 Active, not recruiting - Clinical trials for Cancer of Unknown Primary Site

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

CUPISCO
Start date: July 10, 2018
Phase: Phase 2
Study type: Interventional

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.